I'm intrigued that you seem to dismiss the rationale behind the interest of Novartis in finding a solution for ARDS. The primary cause of death in diseases like Influenza, and I suppose, still, COVID19. Do you not think that Novartis has significant expertise in pharmaeconomics, perhaps superior to your personal opinion. I suspect Novartis will have consulted the databases and done their sums.
And obviously they will have great interest in seeing what the data has to say from the COVID19 / ARDS trial, from the beginning to the end.
Then there are other issues like vascular dysfunction and long Covid.
-
- There are more pages in this discussion • 2,950 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |